OTCMKTS:ARGSQ Argos Therapeutics (ARGSQ) Stock Price, News & Analysis $0.05 0.00 (0.00%) As of 10/10/2019 Add Compare Share Share Stock Analysis Stock Analysis About Argos Therapeutics Stock (OTCMKTS:ARGSQ) Get Argos Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0552-Week Range$0.02▼$0.25VolumeN/AAverage Volume13,394 shsMarket Capitalization$571.70 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Argos Therapeutics was a biotechnology company focused on developing personalized immunotherapies for the treatment of cancer. The company’s approach used a patient’s own dendritic cells, which were loaded with tumor-derived RNA to stimulate an immune response directed at cancer cells. Its lead product candidate was AGS-003, an investigational therapy studied primarily in patients with metastatic renal cell carcinoma. Argos also evaluated its dendritic-cell technology in other cancer settings, but its products were not approved for commercial sale. Argos Therapeutics was headquartered in Durham, North Carolina, and operated as a development-stage company serving the biopharmaceutical market. Following disappointing clinical results and financial difficulties, the company filed for Chapter 11 bankruptcy protection in 2017 and subsequently ceased its prior operations. Jeff Abbey served as the company’s chief executive officer during much of its development period.AI Generated. May Contain Errors. Read More Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARGSQ Stock News HeadlinesUnited Therapeutics price target raised to $400 from $360 at ArgusNovember 1, 2024 | markets.businessinsider.comBest Argos sale discounts, from garden furniture sets to BBQsMay 3, 2024 | uk.style.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.October 13 at 1:00 AM | Profits Run (Ad)ARGSQ Historical DataSeptember 27, 2023 | investing.comSeven Argos stores to shut NEXT month amid plans to close 100 for good by 2024July 29, 2023 | mirror.co.ukMArgos launches massive half price garden furniture sale as the heatwave continuesJune 22, 2023 | mirror.co.ukM2023-2029 mRNA Vaccines & Therapeutics Market Opportunities and ForecastApril 9, 2023 | marketwatch.commRNA Vaccines & Therapeutics Market Share and Forecast till 2031April 6, 2023 | marketwatch.comSee More Headlines ARGSQ Stock Analysis - Frequently Asked Questions How have ARGSQ shares performed this year? Argos Therapeutics' stock was trading at $0.0540 at the beginning of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc (OTCMKTS:ARGSQ) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) EPS for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. When did Argos Therapeutics' stock split? Shares of Argos Therapeutics reverse split before market open on Friday, January 19th 2018.The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Argos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argos Therapeutics investors own include TransEnterix (TRXDW), ChronoScale Corporation Common Stock (CHRN), Editas Medicine (EDIT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cardiff Oncology (TROV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/09/2017Today10/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ARGSQ CIK1105533 Webwww.argostherapeutics.com Phone919-287-6300FaxN/AEmployees122Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.90 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.03Miscellaneous Outstanding Shares10,587,000Free FloatN/AMarket Cap$571.70 thousand OptionableNot Optionable Beta2.47 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:ARGSQ) was last updated on 10/10/2019 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Argos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARGSQ Stock Alerts